IPO Recap | Shares of Mainz Biomed nearly doubled in trading debut

On the last trading day, the NASDAQ Composite index rose0.20%, while the S&P 500 index climbed0.37%, and the Dow Jones Industrial Average added0.56%.

On the last trading day, there was no traditional IPO filed and four new stocks officially listed for trading. Molecular genetics cancer diagnostic company Mainz Biomed surged 99.80% in its trading debut, giving it a market value of $0.12 billion.

Mainz Biomed，formed in 2021，is a molecular genetics cancer diagnostic company to acquire PharmGenomics with the purpose of commercializing its product portfolio in Europe and the US.

PharmGenomics is a manufacturer of in-vitro diagnostic tests with its own molecular genetic laboratory, and has developed several tests for the European market since its 2008 inception.

The company's portfolio consists of ColoAlert, PancAlert, GenoStrip and Legacy Research-Use-Only and IVD tests such as the GenoChips and the HumaSense product line.

Mainz Biomed is commercializing in vitro molecular tests for cancer screening and booked $1 million in revenue for the 12 months ended June 30, 2021.

BriaCell Therapeutics, foudned in , is a clinical stage immunotherapy company. The Company is focused on developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

Its lead drug candidate, Bria-IMT, is a targeted immunotherapy being developed for the treatment of advanced breast cancer. The Company is focused on conducting Phase I/IIa clinical trial of Bria-IMT in a combination study with immune checkpoint inhibitors.

The Company is also focused on development of Bria-OTS, which is an off-the-shelf personalized immunotherapy based on a patient’s HLA-type. Its other pre- clinical candidates include Bria-Pros, Bria-Lung, Bria-Mel, Bria-TILsRx and others.

As if November 7th, it has a market cap of $0.15 billion, with a listed-to-date return of137.03%.